CC
NVO

Centiva Capital’s Novo Nordisk NVO Stock Holding History

Centiva Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
22,000
-117,189
-84% -$5.03M 0.01% 593
2026
Q1 		$5.12M Buy
139,189
+134,189
+2,684% +$6.36M 0.04% 273
2025
Q4 		$254K Sell
5,000
-47,298
-90% -$2.42M ﹤0.01% 909
2025
Q3 		$2.9M Buy
+52,298
New +$3.06M 0.03% 311
2025
Q2 		– Sell
-15,928
Closed -$1.11M – 1913
2025
Q1 		$1.11M Sell
15,928
-15,439
-49% -$1.28M 0.03% 431
2024
Q4 		$2.7M Buy
31,367
+10,469
+50% +$1.13M 0.06% 201
2024
Q3 		$2.49M Buy
20,898
+12,132
+138% +$1.62M 0.05% 360
2024
Q2 		$1.25M Sell
8,766
-795
-8% -$105K 0.02% 663
2024
Q1 		$1.23M Sell
9,561
-1,842
-16% -$219K 0.03% 557
2023
Q4 		$1.18M Buy
11,403
+3,184
+39% +$315K 0.03% 538
2023
Q3 		$747K Buy
8,219
+3,647
+80% +$321K 0.02% 775
2023
Q2 		$370K Buy
+4,572
New +$373K 0.01% 992

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Centiva Capital's NVO Position: Q2 2026 in Review

Centiva Capital reduced its Novo Nordisk (NVO) stake by 84% in Q2 2026, selling an estimated $5.03M and leaving 22,000 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #593.

Centiva Capital first reported a position in NVO in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.12M in Q1 2026. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Centiva Capital held 22,000 shares of Novo Nordisk worth $1.05M as of Q2 2026.
  • Centiva Capital sold 117,189 Novo Nordisk shares in Q2 2026, an estimated $5.03M.
  • Novo Nordisk made up 0.01% of Centiva Capital's portfolio in Q2 2026, its #593 holding.
  • Centiva Capital first reported a position in Novo Nordisk in Q2 2023 and has held it in 12 quarters since.
  • Centiva Capital's Novo Nordisk position peaked at $5.12M in Q1 2026.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.